Table 2.

Flow cytometric analysis of T-cell responses to WT1 (126), WT1 (187), and proteinase 3 in AML patients

PatientNo peptideWT1 (126)WT1 (187)PR3 (169)
0.04 0.27*, 0.27*, 0.08 
0.04 0.10* 0.05 0.06 
0.06 0.08 0.21* 0.09 
0.18 0.16 0.23 0.60* 
0.18 0.11 0.11 0.18 
NA — — — 
0.36 0.40 0.40 0.38 
0.02 0.04 0.04 0.05 
0.02 0.03 0.03 0.02 
10 0.64 ND ND 1.34* 
 0.13 ND ND 0.28* 
 0.03 ND ND 0.45* 
 0.31 0.21 0.32 0.69* 
11 0.28 0.26 0.26 0.41 
12 0.07 0.12 0.12 0.21* 
13 0.04 0.07 0.07 0.14* 
14 NA — — — 
15 NA — — — 
PatientNo peptideWT1 (126)WT1 (187)PR3 (169)
0.04 0.27*, 0.27*, 0.08 
0.04 0.10* 0.05 0.06 
0.06 0.08 0.21* 0.09 
0.18 0.16 0.23 0.60* 
0.18 0.11 0.11 0.18 
NA — — — 
0.36 0.40 0.40 0.38 
0.02 0.04 0.04 0.05 
0.02 0.03 0.03 0.02 
10 0.64 ND ND 1.34* 
 0.13 ND ND 0.28* 
 0.03 ND ND 0.45* 
 0.31 0.21 0.32 0.69* 
11 0.28 0.26 0.26 0.41 
12 0.07 0.12 0.12 0.21* 
13 0.04 0.07 0.07 0.14* 
14 NA — — — 
15 NA — — — 

Percentage of CD3/CD8/IFN-γ–secreting T cells in response to no peptide, WT1 peptides, or proteinase 3 peptide, respectively.

*

Frequencies correspond to positive T-cell responses (2-fold or higher compared with PBMCs not exposed to peptide, with a minimum of 0.05% IFN-γ–producing CD3 CD8 T cells).

T-cell response was analyzed against both WT1 peptides in one sample.

Analysis of different time points in patient 10.

Close Modal

or Create an Account

Close Modal
Close Modal